This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
Hard to say if this is good or bad news, I know everyone wanted the trial to be over because leronlimab was saving lives. Just more of the same, kicks the can further down the road.
I don’t know if it’s good or bad but I guess it didn’t show an overwhelming reason to stop the trial.
I don't think its true or I'd be running for my life. He is the integral piece here though and am counting on his judgement.
The world of pharma not CYDY. 99.99999999999999999999999999999999%
Yeah, the only downside at this time is the race to get to market. If keep kicking the can further down the road, they may get surpassed at some point.
For sure. And that may even be likely if the m/m doesn’t come through. Sounds like they need 30+ more for the s/c to be enrolled and then a month to complete them and god knows how long to do analysis — that’s November.
Yes. I think you will even see a lot of the longs selling and hoping to get in at a cheaper price (lowering their cost base). I'm considering it.
Someone on Yahoo just mentioned that it is after 195 patients are enrolled and not 4 weeks after the 195th patient. I am not sure, but this will make a big difference.
![[icon]](/data/avatars/m/5/5167.jpg?1660313464){kind=avatar}
From the PR:
Interpreting the PR as written, the person on Yahoo is correct but I feel that this is another communication gaffe.
The sources reporting on them are all paid. Even the Cytodyn leader Dr Patterson has a lot of financial interest in the stock price.
All their eggs are now in the m/m basket. If they are just graduated to a phase 3 trial, then this will not only take a hit, but the stock will sink below the Nasdaq threshold.
From here-
If leronlimab was clearly helping patients on the drug, vs the other arm, they'd have stopped the trial and given the other arm leronlimab.From here-
Next week, we will be reporting on CD-12 — safety look at we're going to have. We also going to hopefully have the top-line report for CD-10 completed within 10 days and we would immediately announced and published. When we publish, it's because we are so positive on our results that we want everybody to see every detail of every one of these points.
Seems like they release exactly what they said they would.
From what I’m reading (dunno how true) that is an exceptionally rare thing to have happen and should not have been the expectation.
Yeah, it would've been basically a grand-slam, rather than a homerun.
True.
Yes. It is also the federal government, and while we hope they would finally stop moving at their glacier pace, that probably ain’t gonna be likely.
I've been counting on the interim analysis at 195, hopefully that they will be able to do that. Only problem is they still have patients to fill to get to that number and then its another month before the trial completes and then whatever time it takes to compile and crunch the numbes. That's at least 2 1/2 months from now I think.
Its funny. Everytime you post i think its Wyhatt. Must be the first post thing in here.
I am, I’m only at like 17 grand right now. I’m holding for the long haul though. 17K is really nice, but I will absolutely hate myself if I cash out at 17 but it could’ve been 117. Not even considering it until after uplisting and seeing what comes of that.
Yeah, we all want the grand slam and EUA, but they're still putting bloopers and drag bunts in play
